The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

OMB APPROVAL

OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity			
	D		
CIK (Filer ID Number)	Previous Names	None	Entity Type
0000882291	BISHOP EQU	JITIES INC	X Corporation
Name of Issuer			Limited Partnership
AETHLON MEDICAL INC			H
Jurisdiction of Incorporation/Organi	zation		Limited Liability Company
NEVADA			General Partnership
Year of Incorporation/Organization			Business Trust
Over Five Years Ago			Other (Specify)
Within Last Five Years (Specify	Year)		
Yet to Be Formed			
2. Principal Place of Business an	d Contact Information		
Name of Issuer			
AETHLON MEDICAL INC			
Street Address 1		Street Address 2	
8910 UNIVERSITY CENTER LANE	E, SUITE 660		
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SAN DIEGO	CALIFORNIA	92122	858-459-7800
3. Related Persons			
Last Name	First Name		Middle Name
JOYCE	JAMES		A.
Street Address 1	Street Address 2		
8910 UNIVERSITY CENTER LANE 660	E, SUITE		
City	State/Province/Cou	ıntrv	ZIP/PostalCode
SAN DIEGO	CALIFORNIA	······ <i>j</i>	92122
Relationship: X Executive Officer	_		
Clarification of Response (if Necess	ary):		
Last Name	First Name		Middle Name
TULLIS, PH.D.	RICHARD		H.
Street Address 1	Street Address 2		
8910 UNIVERSITY CENTER LANE 660	E, SUITE		
City	State/Province/Cou	intry	ZIP/PostalCode
SAN DIEGO	CALIFORNIA		92122
Relationship: X Executive Officer	Director Promoter		
Clarification of Response (if Necess	sary):		
Last Name	First Name		Middle Name
BARRY, JR.	FRANKLYN		S.
Street Address 1	Street Address 2		

8910 UNIVERSITY CENTER LAN 660	IE, SUITE		
City	State/Province/Country	ZIP/PostalCode	
SAN DIEGO	CALIFORNIA	92122	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
BROENNIMAN	EDWARD	G.	
Street Address 1 8910 UNIVERSITY CENTER LAN	Street Address 2		
660	2, 30112		
City	State/Province/Country	ZIP/PostalCode	
SAN DIEGO	CALIFORNIA	92122	
Relationship: Executive Officer	_		
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
KENLEY	RODNEY	S.	
Street Address 1	Street Address 2		
8910 UNIVERSITY CENTER LAN 660	IE, SUITE		
City	State/Province/Country	ZIP/PostalCode	
SAN DIEGO	CALIFORNIA	92122	
Relationship: X Executive Officer	X Director Promoter		
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
WARD	PHILLIP		
Street Address 1	Street Address 2		
8910 UNIVERSITY CENTER LAN 660	IE, SUITE		
City	State/Province/Country	ZIP/PostalCode	
SAN DIEGO	CALIFORNIA	92122	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
WORNHAM	THOMAS		
Street Address 1 8910 UNIVERSITY CENTER LAN 660	Street Address 2 IE, SUITE		
City	State/Province/Country	ZIP/PostalCode	
SAN DIEGO	CALIFORNIA	92122	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
SHAH, MD	CHETAN		
Street Address 1	Street Address 2		
8910 UNIVERSITY CENTER LAN 660	E, SUITE		
City	State/Province/Country	ZIP/PostalCode	
SAN DIEGO	CALIFORNIA	92122	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Neces			

Last Name	First Name	Middle Name
FRAKES	JAMES	В.
Street Address 1	Street Address 2	
8910 UNIVERSITY CENTER LANE, SUITE 660		
City	State/Province/Country	ZIP/PostalCode
SAN DIEGO	CALIFORNIA	92122
Relationship: X Executive Officer Director	Promoter	
Clarification of Response (if Necessary):		
4. Industry Group		
Agriculture	Health Care	
Banking & Financial Services	X Biotechnology	Retailing
Commercial Banking		Restaurants
H	Health Insurance	Technology
Insurance	Hospitals & Physicians	Computers
Investing	Pharmaceuticals	Telecommunications
Investment Banking		
Pooled Investment Fund	Other Health Care	Other Technology
Is the issuer registered as an investment company under	Manufacturing	Travel
the Investment Company	Real Estate	Airlines & Airports
Act of 1940?	Commercial	Lodging & Conventions
UYes UNo	Construction	Tourism & Travel Services
Other Banking & Financial Services	REITS & Finance	
Business Services		Other Travel
Energy	Residential	Other
Coal Mining	Other Real Estate	
Electric Utilities		
Energy Conservation		
Environmental Services		
Oil & Gas		
Other Energy		
5. Issuer Size		
Revenue Range OR	Aggregate Net A	sset Value Range
No Revenues		Net Asset Value
\$1 - \$1,000,000	\$1 - \$5,000,00	
片	H	
X \$1,000,001 - \$5,000,000	\$5,000,001 - \$	
\$5,000,001 - \$25,000,000	\$25,000,001 -	
\$25,000,001 - \$100,000,000	\$50,000,001 -	
Over \$100,000,000	Over \$100,000	
Decline to Disclose	Decline to Disc	
Not Applicable	Not Applicable	

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

13. Offering and Sales Amounts			
IOWA NEW JERSEY TEXAS			
State(s) of Solicitation (select all that apply) Check "All States" or check individual States	Foreign/no	on-US	
City NEW YORK	State/Provinc	e/Country	ZIP/Postal Code 10036
546 FIFTH AVENUE, 5TH FLOOR	State/Draving	e/Country	7ID/Doctol Code
Street Address 1	Street Addres	SS 2	
Laidlaw & Co (UK) Ltd.	119037		
(Associated) Broker or Dealer None	(Associated)	Broker or Dealer CRD Number None	
Laidlaw & Co (UK) Ltd.	119037	_	
Recipient	Recipient CF	RD Number None	
12. Sales Compensation			
Minimum investment accepted from any outside investor S	\$12,500 USD		
11. Minimum Investment			
Clarification of Response (if Necessary):		_ _	
Is this offering being made in connection with a business or exchange offer?	combination transaction, suc	h as a merger, acquisition Yes No	
10. Business Combination Transaction			
_	Units	consisting of common stock and common	stock warrants
Security to be Acquired Upon Exercise of Option, Warra Acquire Security	Ot Other Right to	her (describe)	
X Option, Warrant or Other Right to Acquire Another Secu		neral Property Securities	
Debt	片	nant-in-Common Securities	
X Equity	H	poled Investment Fund Interests	
_	Пъ	solod Investment Fund Interests	
9. Type(s) of Securities Offered (select all that apply)			
Does the Issuer intend this offering to last more than one y	/ear? Yes X No		
8. Duration of Offering			
Amendment			
New Notice Date of First Sale 2013-10-30 First Sale	e Yet to Occur		
7. Type of Filing			
	Section 3(c)(7)		
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)	
Rule 506(c)			
X Rule 506(b)	Section 3(c)(5)	Section 3(c)(13)	
Rule 505	Section 3(c)(4)	Section 3(c)(12)	
Rule 504 (b)(1)(iii)	Section 3(c)(3)	Section 3(c)(11)	
Rule 504 (b)(1)(ii)			
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)	
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)	
	Investment Company	Act Section 3(c)	

\$2,000,000 USD or Indefinite

Total Offering Amount

Total Amount Sold \$230,000 USD				
Total Remaining to be Sold \$1,770,000 USD or Indefinite				
Clarification of Response (if Necessary):				
14. Investors				
Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.				
Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:				
15. Sales Commissions & Finder's Fees Expenses				
Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.				
Sales Commissions \$52,600 USD Estimate				
Finders' Fees \$0 USD Estimate				
Clarification of Response (if Necessary):				
Includes a 2% non-accountable expense and \$25,000 activation fee. The Company also issued 276,000 warrants to Laidlaw & Company in connection with the units sold.				
16. Use of Proceeds				
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.				
\$0 USD Estimate				
Clarification of Response (if Necessary):				
In the ordinary course, the issuer may use some of the proceeds of the offering to pay salaries to management.				
Signature and Submission				

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
AETHLON MEDICAL INC	/s/ James B. Frakes	James B. Frakes	Chief Financial Officer	2013-11-08

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

^{*} This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.